2015 American Transplant Congress
Number of Antigen Targets: A Key Parameter for Accurate Flow Cytometry Crossmatch Interpretation of Weak DSA
BACKGROUND: Flow cytometry crossmatch (FCXM) results are used to assess the safety of a transplant across pre-existing DSA. The number of targets on donor cells…2015 American Transplant Congress
Improving the Predictive Value of the Virtual Crossmatch: Is the C1Q Assay Needed?
The criteria for reporting unacceptable HLA antigens of renal transplant candidates differ greatly between transplant centers. In the attempt to refine these criteria, the experience…2015 American Transplant Congress
Outcome of Bortezomib/Plasmapheresis for the Sensitized Patient Awaiting Heart Transplant
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Allosensitization of patients (pts) awaiting heart transplantation is a significant challenge as it prolongs the time to transplant, increases wait-list mortality and increases risk…2015 American Transplant Congress
Bortezomib Treatment in Antibody Mediated Rejection After Kidney Transplantation
BackgroundSeveral studies demonstrated bortezomib therapy for antibody-mediated rejection (AMR) in renal transplants. However, the treatment efficacy according to target antigen or occurrence time of AMR…2015 American Transplant Congress
Are DQA Antibodies Real?
Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Antibodies specific for HLA-DQ antigens appear to be increasing in frequency in the post-transplant period and are difficult to reduce effectively with desensitization protocols using…2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…2015 American Transplant Congress
Incidence of De Novo Donor Specific Antibodies in Kidney Transplant Recipients
The reported incidence and risk factors for the development of de novo donor specific antibodies (dnDSA) are variable. Although dnDSA is a negative predictor of…2015 American Transplant Congress
Differences in Reactivity of HLA-Specific Antibodies May Be Explained By Differences in Their Affinities for Selected Epitopes on HLA Proteins
Affinity of IgG immunoglobulins for antigen varies and matures within the evolution of immune responses. Affinity is likely to be different for different epitope-antibody interactions…2015 American Transplant Congress
Impact of Pretransplant Pregnancy On Immunization and Immunologic Outcome in Kidney Transplantation
BACKGROUND:The detailed impact of pretransplant pregnancy on HLA alloimmunization and outcome after kidney transplantation is so far not well known.PATIENTS AND METHODS:A retrospective single center…2015 American Transplant Congress
Pre-Transplant Donor Specific Antibody With Negative Flow-Crossmatch Was Related to Higher Acute Rejection But Not to Poor Graft Survival
Background: DSA have been associated to lower graft survival and a higher humoral rejection rate, but there is a concern about the clinical impact of…
American Transplant Congress abstracts